Besins Healthcare Strengthens Innovation Capabilities with Acquisition of UniD Manufacturing, a Specialist in Long-Acting Drug Delivery Technologies
2.7.2026 11:00:00 CEST | Business Wire | Press Release
Besins Healthcare, a global pharmaceutical company specializing in hormonal health, today announced the acquisition of UniD Manufacturing, a Belgium-based pharmaceutical development and manufacturing company with more than 20 years of recognized expertise in long-acting drug delivery technologies.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701779777/en/
Besins Healthcare Strengthens Innovation Capabilities with Acquisition of UniD Manufacturing, a Specialist in Long-Acting Drug Delivery Technologies
This acquisition brings together two highly compatible areas. Besins Healthcare brings deep expertise in hormone therapies for women’s and men’s health, including treatments such as Estrogel®/Oestrogel® (estradiol)2 and Utrogestan®3 (micronized progesterone) for women, and Androgel®/Testogel®4 (testosterone) for men. UniD contributes advanced capabilities in technologies that can enable more differentiated, less frequently administered treatment approaches.
UniD is one of very few companies worldwide that work with the advanced polymer technology used in the development and manufacture of complex long-acting delivery systems, such as implants and vaginal rings.1
Besins Healthcare will acquire the UniD site located in Seraing, Belgium, and 52highly skilled professionals will transfer to the company. As part of this new chapter, UniD Manufacturing will be renamed Besins Healthcare PharmTech and will progressively become a center of excellence dedicated to innovation and future development projects. In the immediate term, UniD will continue to operate as usual and serve its current clients with the same professionalism and commitment.
“This acquisition unites two teams with deep and complementary expertise, and we couldn't be more pleased to welcome UniD to Besins Healthcare," said Nicolas and Alexandre Besins, Co-CEOs, Besins Healthcare. "This is a natural partnership for both companies, and we are excited about what lies ahead."
"We are proud of what the UniD team has built over the past 20 years, and we are delighted to see those capabilities take on a new dimension as part of Besins Healthcare," said Marc Foidart, Executive Chairman at UniD Manufacturing, who will step down from his role. "The UniD team looks forward to innovating further with Besins Healthcare, as well as continuing to serve our existing clients with the same commitment they have always received."
Over the last 10 years, Besins Healthcare has experienced sustained, double-digit growth, with revenues reaching over €700 million in 2025, continuing a trajectory that has established the company as one of the fastest-growing companies in the hormonal health sector.5
UniD Manufacturing’s Headquarters in Seraing, Belgium
About UniD Manufacturing
UniD Manufacturing is a Belgium-based pharmaceutical CDMO specializing in long-acting drug delivery technologies and advanced polymer-based pharmaceutical formulations. The company provides development and manufacturing services for complex therapeutic products, such as implants, inserts, and vaginal ring technologies, supporting pharmaceutical and biotechnology partners from development through commercial supply. www.unid-manufacturing.com
About Besins Healthcare
Besins Healthcare is a global leader and specialist in hormonal health, and the only company in the world offering a complete portfolio of bioidentical hormones – progesterone, estradiol and testosterone – for both women and men. A family-owned business with more than five generations of heritage, the company sells its medicines across 114 countries through 22 wholly owned subsidiaries.5 In 2025, Besins Healthcare reported revenues of over €700 million.5 Estrogel®, Utrogestan®, Androgel®, Testogel® are trademarks owned by Besins Healthcare. www.besins-healthcare.com.
1 We are UniD. Available at https://www.unid-manufacturing.com/. Last accessed June 2026
2 Oestrogel Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/353/smpc#gref. Last accessed June 2026.
3 Utrogestan 100mg capsules. Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/352/smpc#gref Last accessed June 2026.
4 Testogel®. Summary of product characteristics. Available at: https://www.medicines.org.uk/emc/product/8919/smpc. Last accessed June 2026.
5 Data on file.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260701779777/en/
Contacts
Media contact: Sébastien Grilli, sgrilli@besins-healthcare.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press Release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press Release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 14:00:00 CEST | Press Release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press Release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom